Nutriband Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTRB research report →
Price Chart
About the company
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse.
- CEO
- Gareth Sheridan
- IPO
- 2021
- Employees
- 13
- HQ
- Orlando, FL, US
Get TickerSpark's AI analysis on NTRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $81.20M
- P/E
- -11.68
- Fwd P/E
- 4.25
- PEG
- -0.13
- P/S
- 50.20
- P/B
- 15.24
- EV/EBITDA
- -11.45
- Div Yield
- 0.00%
- Gross Margin
- 33.14%
- Op Margin
- -435.58%
- Net Margin
- -430.43%
- ROE
- -109.02%
- ROIC
- -126.99%
Latest fiscal year · YoY change
- Revenue
- $2.04M-4.8%
- Gross Profit
- $566.31K-19.0%
- Op Income
- $-8,317,961
- Net Income
- $-8,229,632+21.5%
- EPS
- $-2.58-160.6%
- OCF Growth
- -11.0%
- FCF Growth
- -8.8%
- 52W High
- $9.19
- 52W Low
- $2.80
- 50D MA
- $5.18
- 200D MA
- $4.21
- Beta
- 1.93
- RSI (14)
- 50
- Avg Volume
- 61.61K
No earnings-call transcripts are available for NTRB yet.
- Free Float
- 43.4%
- Shares Outstanding
- 12.16M
- Float Shares
- 5.28M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 202.74K | 0 |
| Vanguard Capital Management LLC | 174.93K | 0 |
| Geode Capital Management, LLC | 62.49K | ▼ 7.56K |
| Vanguard Fiduciary Trust Co | 25.11K | 0 |
| State Street Corp | 24.97K | 0 |
| Citadel Advisors LLC | 19.00K | ▲ 19.00K |
| Northern Trust Corp | 11.57K | ▼ 2.38K |
| Haven Private, LLC | 11.37K | 0 |
| Blackrock, Inc. | 10.66K | ▲ 1.12K |
| Advisor Group Holdings, Inc. | 3.68K | ▼ 1.17K |
| Vanguard Global Advisers, LLC | 2.70K | 0 |
| Wells Fargo & Company/Mn | 2.60K | 0 |
Held by 22 ETFs
Biggest fund positions in NTRB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 25 | Sheridan Gareth | other | 0 |
| Jan 29, 25 | Sheridan Gareth | other | 29,333 |
| Mar 20, 24 | Sheridan Gareth | other | 97,500 |
| Jan 23, 25 | Goodman Gerald | other | 17,667 |
| Mar 19, 24 | Goodman Gerald | other | 75,000 |
| Oct 27, 23 | Goodman Gerald | other | 60,085 |
| Jun 5, 24 | Goodman Gerald | other | 60,085 |
| Mar 20, 24 | Goodman Gerald | other | 75,000 |
| Jun 6, 24 | Goodman Gerald | other | 87,500 |
| Mar 20, 24 | MELNIK SERGUEI | other | 97,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NTRB coverage
Recent articles, reports, and earnings notes.
No research on NTRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NTRB report →Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
globenewswire.com · Oct 1
Head to Head Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)
defenseworld.net · Oct 1
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
globenewswire.com · Sep 29
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
globenewswire.com · Sep 22
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
globenewswire.com · Sep 9
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
globenewswire.com · Sep 8
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
globenewswire.com · Aug 13
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
globenewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.